Successful Treatment with Imatinib Mesylate in a Case of Minor BCR-ABL-Positive Acute Myelogenous Leukemia

  • Katsuro Ito
  • Kazunori Tominaga
  • Toshiya Suzuki
  • Itsuro Jinnai
  • Masami Bessho
Case Report

Abstract

Philadelphia (Ph) chromosome-positive acute myelogenous leukemia (AML) is a rare disease that is resistant to conventional antitumor chemotherapy and has a poor prognosis. We describe a case of Ph chromosome-positive AML in which imatinib mesylate was used and a favorable outcome was obtained. A 64-year-old man was found to have Ph chromosome-positive, minor BCR-ABL-positive AML. Remission could not be induced by remission induction therapy with antitumor agents. Because the patient had a serious concomitant infectious disease, administration of 600 mg/day of imatinib mesylate, a specific inhibitor of BCR-ABL tyrosine kinase, was started after written informed consent was obtained. Complete cytogenetic response (CCR) was achieved without serious adverse events and persisted for more than 1 year. Our results suggested that imatinib mesylate was very useful for treating Ph chromosome-positive AML.

Key words

Imatinib mesylate Minor BCR-ABL AML 

References

  1. 1.
    Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947–4952.PubMedGoogle Scholar
  2. 2.
    Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–932.PubMedGoogle Scholar
  3. 3.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037.PubMedCrossRefGoogle Scholar
  4. 4.
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652.PubMedCrossRefGoogle Scholar
  5. 5.
    Savage DG, Antman KH. Imatinib mesylate: a new oral target therapy. N Engl J Med. 2002;346:683–693.PubMedCrossRefGoogle Scholar
  6. 6.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–1042.PubMedCrossRefGoogle Scholar
  7. 7.
    Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study. Blood. 1992;80:2983–2990.PubMedGoogle Scholar
  8. 8.
    Paietta E, Racevskis J, Bennett JM, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia. 1998;12:1881–1885.PubMedCrossRefGoogle Scholar
  9. 9.
    Katsuno M, Yamashita S, Sadamura S, et al. Late-appearing Philadelphia chromosome in a patient with acute nonlymphocytic leukaemia derived from myelodysplastic syndrome: detection of P210- and P190-type bcr/abl fusion gene transcripts at the leukaemic stage. Br J Haematol. 1994;87:51–56.PubMedCrossRefGoogle Scholar
  10. 10.
    McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol. 1989;9:1866–1874.PubMedGoogle Scholar
  11. 11.
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566.PubMedCrossRefGoogle Scholar
  12. 12.
    Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blastic crisis: results of a phase II study. Blood. 2002;99:3530–3539.PubMedCrossRefGoogle Scholar
  13. 13.
    Yamaguguchi M, Konishi I. Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia. Jpn J Clin Hematol. 2003;44:254–256.Google Scholar
  14. 14.
    Viniou N-A, Vassilakopoulos TP, Giakoumi X, et al. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1(+) acute myeloid leukemia. Eur J Haematol. 2004;72:58–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Scappini B, Onida F, Kantarjian HM, et al. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res. 2001;7:3884–3893.PubMedGoogle Scholar
  16. 16.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880.PubMedCrossRefGoogle Scholar
  17. 17.
    Ottomann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965–1971.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  • Katsuro Ito
    • 1
  • Kazunori Tominaga
    • 1
  • Toshiya Suzuki
    • 1
  • Itsuro Jinnai
    • 2
  • Masami Bessho
    • 2
  1. 1.Ogawa Red Cross HospitalSaitamaJapan
  2. 2.First Department of Internal MedicineSaitama Medical SchoolSaitamaJapan

Personalised recommendations